CTEC
NEUTRALConvaTec Group Provides Regulatory Update
The healthcare company has announced a regulatory filing regarding a change in shareholding.
ConvaTec Group
275.60GBX
-0.07%
Market Cap
5.63B
Volume
7.01M
106% of avg
P/E Ratio
21.20
EPS (TTM)
0.13
Beta
0.66
Day Range
273.40p - 276.40p
52 Week Range
211.80p275.60p276.40p
275.60p
Upcoming Events
CTEC
NEUTRALConvaTec Group Announces Regulatory Filing
The healthcare company has made a regulatory filing, but no further details are provided.
CTEC
NEUTRALConvaTec Group Announces Regulatory Filing
The healthcare company has filed a regulatory announcement, but no further details are provided.
CTEC
NEUTRALConvaTec Responds to LCD Postponement in US
The healthcare company welcomes the postponement of LCDs in the US, which will allow continued access to its InnovaMatrix product for Medicare patients.
CTEC
NEUTRALConvaTec Announces Change in Major Shareholding
The healthcare company has reported a change in major shareholding, with FIL Limited increasing its stake to over 6%.
CTEC
NEUTRALConvaTec Announces Director Share Dealings
The healthcare company has disclosed details of a PDMR's vesting of shares under the long-term incentive plan and subsequent sale of shares to cover tax liabilities.
CTEC
NEUTRALConvaTec CEO Karim Bitar Vests Shares Under Incentive Plans
The healthcare company announced the vesting of shares for its CEO under long-term incentive plans.
CTEC
NEUTRALConvatec Group Plc Announces Director/PDMR Shareholding Changes
The medical products and technologies company announces changes to director and PDMR shareholdings through the grant of incentive awards.
CTEC
NEUTRALConvatec Group PLC Publishes Annual Report and AGM Notice
The healthcare company has published its annual report and notice of annual general meeting, a routine regulatory update.
CTEC
GOODConvatec Reports Strong FY24 Results with Double-Digit Profit Growth
The medical products and technologies group reported strong FY24 results with 7.7% organic revenue growth and 13.7% increase in adjusted EPS. Management expressed confidence in the FY25 outlook, targeting continued growth and margin expansion.